Clinical Trials Logo
  1. Home
  2. Gastric Carcinoma
  3. NCT05811546
  4. Details
NCT05811546 Clinical Trial

Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Gastric Carcinoma Clinical Trial

Official title:
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05811546
Other study ID # Epigenetics Gastric Carcinoma
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date December 31, 2024

Study information
Verified date March 2023
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this cross-sectional study is to evaluate epigenetic modifications in gastric carcinogenesis, mainly in H. pylori gastritis vs gastric carcinoma. The main question[s] it aims to answer are: - How does H. pylori infection cause gastric cancer? - Can DNA methylation and other epigenetic changes predict and affect the development of gastric cancer? Formalin-fixed-paraffin-embedded tissue specimens will be obtained and reviewed for comparison between epigenetic changes in H. pylori gastritis and gastric adenocarcinoma.

Recruitment information / eligibility
Status Recruiting
Enrollment 68
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 100 Years
Eligibility Inclusion Criteria: - Resected specimens and endoscopic guided biopsies of intestinal type gastric carcinoma, H. Pylori associated gastritis, and non-H. Pylori gastritis with: - Available full clinical data: (age, sex, complaint, findings in clinical examination). - Full data of previous endoscopy and radiology. Exclusion Criteria: - Cases of diffuse type gastric carcinoma. - Any case of gastric cancer, H. Pylori associated gastritis, non-H. Pylori gastritis, benign gastric lesions with missing clinical, endoscopic, radiologic or follow-up data. - Cases with no available H&E stained slides or formalin fixed paraffin embedded block.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Immunohistochemical staining for DNMT1 and EZH2
Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.

Locations
Country Name City State
Egypt Assiut University Assiut

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Difference in DNMT1 and EZH2 expression. Histopathological evaluation of routine H&E slides and immunohistochemical markers to compare the intensity and extent of epigenetic changes in both H. Pylori associated gastritis and gastric carcinoma. two years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Not yet recruiting NCT03599778 - XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma Phase 1/Phase 2
Terminated NCT00256321 - Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma Phase 2
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Recruiting NCT02317471 - Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 Phase 1/Phase 2
Active, not recruiting NCT03735511 - A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting NCT05596188 - Anxiety Before Non-cardiac Surgery in Adults
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Terminated NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT01348009 - Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer Phase 1/Phase 2
Recruiting NCT00639522 - Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma Phase 1
Recruiting NCT05229809 - Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer Phase 4
Recruiting NCT02409199 - A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Phase 2/Phase 3
Completed NCT00970138 - Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer Phase 2/Phase 3
Recruiting NCT06408220 - Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer N/A
Recruiting NCT04443036 - Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma N/A
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2